Friday, January 28, 2022 Current Time : 0:51 in Tehran
Created Date : Monday, June 15, 2020   Update Date : Saturday, November 6, 2021    Visit : 968


Dr. Payam Peymani

Assistant Professor and Director of the Department

Pharmacoepidemiology and Pharmacoeconomics Department

Health Policy Research Center, School of Medicine

Shiraz University of Medical Sciences



Visiting Professor

Department of Clinical Pharmacology & Toxicology, University Hospital Zurich, Zurich, Switzerland


Address: University Hospital Zurich, RAE E, Rämistrasse 100,8091, Zurich, Switzerland






Payam Peymani is an assistant professor and the head of the Department of Pharmacoepidemiology and Pharmacoeconomics, Health Policy Research Center, School of Medicine, Shiraz University of Medical Sciences (SUMS). In addition, Dr. Peymani actively works at SUMS Autophagy Research Center. It is worth mentioning that Dr. Peymani received his Doctor of Pharmacy (Pharm.D.) degree at SUMS School of Pharmacy and did his PhD in Clinical Pharmacology (Pharmacoepidemiology) at SUMS Health Policy Research Center in 2016.

He has also been appointed Visiting Professor to visit the Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Switzerland to continue academic collaboration with this University Hospital. In addition to all the above mentioned responsibilities, Dr. Peymani is the Director of Permanent Secretariat of Euro-Asian Pharmacoepidemiology Congress (EAPEC). 

Dr. Peymani is the author of more than 60 peer-reviewed papers, has given presentations in more than 35 international congresses and symposia and has been the reviewer of various international scientific journals. Dr. Peymani has more than 6 years of experience in designing and conducting clinical trials, population based studies in Pharmacoepidemiology.  He has taken different positions such as a Clinical Research Manager, a Senior Clinical Research Associate, a Statistical and Epidemiological Consultant for Clinical Trials projects, and postdoctoral fellowship and professorship. Dr. Peymaniʼs expertise is in designing, conducting and doing analysis-documentation of clinical trials, monitoring the progress of clinical studies and assessing standard operating procedures (SOPs) and the drug safety/pharmacovigilance of projects. Currently, he is involved in Pharmacoepidemiology, Pharmacovigilance and Drug Safety Studies. Among his main research interests are designing and conducting clinical trials and doing Pharmacoepidemiology and Drug Safety Evaluation.


Research Priorities:

  • Pharmacoepidemiology
  • Drug Safety, Pharmacovigilance
  • Clinical Trial (Clinical Trials Design and Management)
  • Population Based Study
  • Clinical Pharmacology


Previous Academic Collaborations with the Target University:

Project Title: Design and Implementation of Drug-Induced Liver Injuries Algorithm in Hospital

A Prospective Analysis from Laboratory Signals

Funded by: University of Zurich and University Hospital Zürich, Zürich, Switzerland

Role: Main investigator

Year: 2019-2022


Project Title: Apoptosis, Autophagy, and Endoplasmic Reticulum Stress in Autoimmune Hepatitis: A Clinical Pilot Study

Funded by: Manitoba University, Canada and Shiraz University of Medical Sciences, Iran,

Role: Co-investigator

Year: 2013-2015


Project Title: Chloroquine Therapy for Non-Responsive HCV Patients Genotype

Funded by: Manitoba University, Canada and Shiraz University of Medical Sciences, Iran

Role: Co-investigator

Year: 2012-2014


Project Title: Predictors of Switching to Insulin in Oral Anti Diabetic (Oral Hypoglycemic) Agent Users (Population Based Study)

Funded by: Erasmus MC (Rotterdam, the Netherlands)

Role:  Co-investigator

Year: 2017-2021


Project Title: Medication Use Review (MUR) in Community Pharmacists

Funded by: Department of Pharmacy, Faculty of Medicine, University of Tartu, Tartu, Estonia

Role: Main investigator

Year: 2019-2021


Number and the Duration of Previous Visits to the Target University:

Duration: one year

Position: Postdoctoral Fellowship of Pharmacoepidemiology and Pharmacovigilance, Department of Clinical Pharmacology & Toxicology, University Hospital Zürich, Zürich, Switzerland.

Project Title: Post marketing surveillance of liver injury caused by drugs: prospective analysis of drug-induced liver injury cases in a major Swiss university hospital and comparison with retrospective cases extracted from the Swiss Pharmacovigilance database

Funding: received 100,000 CHF from University of Zurich, Switzerland